What's breaking now, across thousands of outlets.
(RTTNews) - Gain Therapeutics, Inc. (GANX) on Tuesday reported a narrower net loss for the third quarter of 2026 compared with the same period in 2025, as reduced research and development and general and administrative expenses lowered overall operating costs.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
The agreement clears the way next week for approval of Google's $10 million deal to acquire Spirit data to train AI models.
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Key PointsCounterpoint Research says Sandisk's NAND flash market share is back at 11%.
Accenture's 11.3% net margins and $11.6B free cash flow contrast sharply with Intuit's 21.3% margins but higher valuation multiples, a key tension for value-conscious investors.
A group of financial firms including Goldman Sachs Group Inc., Citigroup Inc., Banco Santander SA and Deutsche Bank AG …
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
